Onvansertib effectively targets the once “undruggable” KRAS-mutation present in 50% of colorectal cancerNew Podcast

Turning the Tide on Cancer

Investing in Cardiff Oncology to Provide New Treatment Options for Cancers with the Greatest Medical Need

Analyst Coverage


Cardiff Oncology is followed by the analysts. Please note that any opinions, estimates or forecasts regarding Cardiff Oncology, Inc's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Cardiff Oncology, Inc or its management. Cardiff Oncology, Inc does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.